• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Rythmical
    / Unipharm


    Active Ingredient
    Disopyramide Phosphate 100 mg, 150 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Capsules

    60 X 100 mg

    full basket chart 24789 18293

    Capsules

    60 X 150 mg

    full basket chart 24790 18238

    Related information


    Indications

    Atrial and ventrical arrhythmia.


    Contra-Indications

    Known hypersensitivity. Cardiogenic shock or in patients with second or third degree AV block if no pacemaker is present. It should not be given at all, or should be given with extreme caution, to patients with acute infarction or extensive myocardial disease, such as valvular disease, chronic auricular fibrillation of long-standing congestive heart failure, cardiac enlargement, mitral stenosis, recent coronary occlusion or a history of embolism. The drug is contraindicated in digitalis intoxication.


    Special Precautions

    Should not be given when a patient is taking anticholinergic drugs. Severe hypotension following disopyramide administration has been observed, usually in patients with primary cardiomyopathy or inadequately compensated congestive heart failure. If hypotension develops, treatment should be discontinued promptly. Pregnancy. Patients with partial heart block. The mild anticholinergic effects of Rythmical require that its therapeutic use be balanced against these effects in patients with glaucoma, or a tendency for urinary retention. Patients with atrial flutter or fibrillation should be digitalized prior to Rythmical administration. Patients with significant renal disease. Patients with severe hypokalemia. Prolongation of the QT interval (corrected) may occur, particularly in response to high doses. If excessive QT prolongation (greater than 25%) is observed and if ectopy continues, the patient should be monitored closely and consideration be given to discontinuing Rythmical. Rythmical treatment should not commence until at least one half-life after discontinuation of other class I antiarrhythmic agents. Rythmical should be administered cautiously to patients who are receiving, or who have recently received, other antiarrhythmic drugs, including beta-blockers.


    Side Effects

    Dry mouth, blurred vision and urinary retention. Other reported side effects include hypokalemia, heart failure, nausea, fatigue, muscle aches or weakness, dizziness, diarrhea and hypoglycemia. Photosensitivity reactions.


    Drug interactions

    β-blockers, anticholinergics, thiazides and loop diuretics, other antiarrhythmics. Liver enzyme inducers, e.g. rifampicin, erythromycin.


    Manufacturer
    Trima Israel Pharmaceutical Products Maabarot Ltd. Israel
    CLOSE